Neuroprotection in Huntington;s Disease

Author(s): Raphael M. Bonelli , Anna K. Hodl , Hans-Peter Kapfhammer .

Journal Name: Letters in Drug Design & Discovery

Volume 2 , Issue 2 , 2005

Become EABM
Become Reviewer

Abstract:

Minocycline, the 7-dimethylamino- 6-dimethyl-desoxytetracycline hydrochloride, is a caspase-1 inhibitor and may serve as anti-apoptotic agent, thereby acting neuroprotective. It directly inhibits both caspase-independent and -dependent mitochondrial cell death pathways, and decreases inducible nitric oxide synthetase activity. Minocycline delays disease progression in the transgenic mouse model of Huntington;s disease (HD), extending survival by 14%. HD is a late onset relentlessly progressive, neurodegenerative disorder with currently no cures or even effective therapies, death occurring 15 years after onset. In this review, recent clinical and preclinical data on minocycline in HD and neuroprotective alternatives discussed.

Keywords: neurodegenerative disorder, gliosis, highly unsaturated fatty acids, glutamate, nmda-receptor antagonist, gabaergic neurotransmission

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 2
ISSUE: 2
Year: 2005
Page: [143 - 147]
Pages: 5
DOI: 10.2174/1570180053175133
Price: $58